Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?

SIMPLE SUMMARY: Data on the efficacy and safety of pharmacotherapy for advanced non-small cell lung cancer (NSCLC) with poor performance status (PS) 2 are insufficient. Cytotoxic chemotherapy for patients with PS 2 is insufficiently effective, and there are concerns about toxicity. Immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Satoshi, Naito, Tateaki, Miura, Satoru, Ito, Kentaro, Furuya, Naoki, Misumi, Toshihiro, Ogura, Takashi, Kato, Terufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562911/
https://www.ncbi.nlm.nih.gov/pubmed/36230785
http://dx.doi.org/10.3390/cancers14194861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562911/
https://www.ncbi.nlm.nih.gov/pubmed/36230785
http://dx.doi.org/10.3390/cancers14194861

Ejemplares similares